The current valuation score of Protalix Biotherapeutics Inc is 6.19, ranking 147 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 12.42, which is 435.63% below the recent high of 66.55 and 324.35% above the recent low of -27.88.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.